Facebook-f Linkedin-in

Gynaecological Cancer

Key guidelines for oncology healthcare professionals are listed below

NICE Clinical Guideline Ovarian cancer: recognition and initial management CG122
NICE Diagnostics Guidance Testing strategies for Lynch syndrome in people with endometrial cancer DG42
NICE Interventional Procedures Guidance Laparoscopic hysterectomy (including laparoscopic total hysterectomy and laparoscopically assisted vaginal hysterectomy) for endometrial cancer IPG356
NICE Interventional Procedures Guidance Minimally invasive radical hysterectomy for early stage cervical cancer IPG686
NICE Interventional Procedures Guidance Ultra-radical (extensive) surgery for advanced ovarian cancer IPG470
NICE Technology Appraisal Bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) TA353
NICE Technology Appraisal Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) TA560
NICE Technology Appraisal Guidance Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer TA284
NICE Technology Appraisal Guidance Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer TA285
NICE Technology Appraisal Guidance Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) TA901
NICE Technology Appraisal Guidance Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency TA779
NICE Technology Appraisal Guidance Guidance on the use of paclitaxel in the treatment of ovarian cancer TA55
NICE Technology Appraisal Guidance Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first line-platinum-based chemotherapy TA673
NICE Technology Appraisal Guidance Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer TA784
NICE Technology Appraisal Guidance Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy TA598
NICE Technology Appraisal Guidance Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer TA620
NICE Technology Appraisal Guidance Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after two or more courses of platinum-based chemotherapy TA908
NICE Technology Appraisal Guidance Olparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer TA693
NICE Technology Appraisal Guidance Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer TA885
NICE Technology Appraisal Guidance Pembrolizumab with Lenvatinib for previously treated advanced or recurrent endometrial cancer TA904
NICE Technology Appraisal Guidance Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer TA611
NICE Technology Appraisal Guidance Topotecan for the treatment of recurrent and stage IVB cervical cancer TA183
NICE Technology Appraisal Guidance Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer TA389

Guidelines

Access key guidelines for oncology healthcare professionals

Click here

Resources

All the major resources from the world of oncology

Click here

Podcasts

We bring you informative podcasts with UK oncology experts

Click here

Events

Don't miss the latest oncology events in the UK

Click here

Are you a healthcare professional?

This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

Yes
No